The objective of the Children's Hospital National Medical Center (CHNMC) is to actively pursue investigations of the therapy, biology, and epidemiology of childhood malignancies through total participation in the Children's Cancer Study Group (CCSG). Investigators from CHNMC will continue to provide scientific and administrative leadership of these activities. CHNMC will enter all eligible patients from the institution and encourage entry of all eligible patients from its affiliate network on group wide studies of multimodality therapy of acute leukemia and pediatric solid tumors. CHNMC will continue to develop and participate in limited institution pilot (toxicity and/or feasibility) studies incorporation novel therapeutic strategies for CNS preventive therapy in childhood ALL with potential group-wide applicability. CHNMC will continue as one of the most active CCSG participants in investigational drug (Phase I and Phase II) studies, particularly those investigating plasma and/or CSF pharmacokinetics. CHNMC will exhibit compliance with protocol specified therapy as well as required evaluations and will submit complete and accurate data to the Operations Office in a timely fashion. CHNMC will expand its CCSG reference laboratory activity of immunophenotypic analysis for ALL studies and will continue to conduct independent and collaborative investigations of differences in cell biology utilizing biochemical parameters (polypeptide analysis, oncogene products, membrane ganglioside composition) and molecular genomic rearrangements which may provide insights of prognostic and therapeutic significance. CHNMC will participate in all CCSG cancer biology studies requiring submission of biologic samples to resource laboratories within the group. CHNMC will participate in case-controlled epidimiologic studies of childhood cancer to investigate the possible relationship of genetic predisposition and pre- and post-natal environmental factors oon the development of malignancy. CHNMC investigators will provide scientific leadership of such investigations within biologically-defined subgroups of patients with ALL, particularly infants less than 1 year of age. As the outcome for children with cancer has improved, CHNMC investigators will participate in the formulation of groupwide studies to examine the long-term impact of successful anti-cancer therapy on all aspects of growth and development.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA003888-34
Application #
3555787
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1976-12-01
Project End
1993-11-30
Budget Start
1990-12-01
Budget End
1991-11-30
Support Year
34
Fiscal Year
1991
Total Cost
Indirect Cost
Name
Children's Research Institute
Department
Type
DUNS #
City
Washington
State
DC
Country
United States
Zip Code
20010
Baruchel, Sylvain; Pappo, Alberto; Krailo, Mark et al. (2012) A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: a report from the Children's Oncology Group. Eur J Cancer 48:579-85
Potter, Samara L Poplack; Berg, Stacey; Ingle, Ashish Mark et al. (2012) Phase 2 clinical trial of intrathecal topotecan in children with refractory leptomeningeal leukemia: a Children's Oncology Group trial (P9962). Pediatr Blood Cancer 58:362-5
Allen, Jeffrey; Donahue, Bernadine; Mehta, Minesh et al. (2009) A phase II study of preradiotherapy chemotherapy followed by hyperfractionated radiotherapy for newly diagnosed high-risk medulloblastoma/primitive neuroectodermal tumor: a report from the Children's Oncology Group (CCG 9931). Int J Radiat Oncol Biol Phys 74:1006-11
Shamberger, Robert C; LaQuaglia, Michael P; Gebhardt, Mark C et al. (2003) Ewing sarcoma/primitive neuroectodermal tumor of the chest wall: impact of initial versus delayed resection on tumor margins, survival, and use of radiation therapy. Ann Surg 238:563-7; discussion 567-8
Casillas, Jacqueline N; Woods, William G; Hunger, Stephen P et al. (2003) Prognostic implications of t(10;11) translocations in childhood acute myelogenous leukemia: a report from the Children's Cancer Group. J Pediatr Hematol Oncol 25:594-600
Davies, Stella M; Bhatia, Smita; Ross, Julie A et al. (2002) Glutathione S-transferase genotypes, genetic susceptibility, and outcome of therapy in childhood acute lymphoblastic leukemia. Blood 100:67-71
Wells, Robert J; Reid, Joel M; Ames, Matthew M et al. (2002) Phase I trial of cisplatin and topotecan in children with recurrent solid tumors: Children's Cancer Group Study 0942. J Pediatr Hematol Oncol 24:89-93
Lange, Beverly J; Bostrom, Bruce C; Cherlow, Joel M et al. (2002) Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 99:825-33
Ou, Shu Xiao; Han, Dehui; Severson, Richard K et al. (2002) Birth characteristics, maternal reproductive history, hormone use during pregnancy, and risk of childhood acute lymphocytic leukemia by immunophenotype (United States). Cancer Causes Control 13:15-25
Cairo, M S; Krailo, M D; Morse, M et al. (2002) Long-term follow-up of short intensive multiagent chemotherapy without high-dose methotrexate ('Orange') in children with advanced non-lymphoblastic non-Hodgkin's lymphoma: a children's cancer group report. Leukemia 16:594-600

Showing the most recent 10 out of 25 publications